The AACE update to its 2026 algorithm for the management of type 2 diabetes includes a new section on diabetes classification.

Insulin is essential for managing blood sugar in type 2 diabetes, helping the body use sugar for energy. Different types of insulin, such as rapid-acting and long-acting, affect the body differently ...

Please provide your email address to receive an email when new articles are posted on . Of 20 hospitals providing insulin algorithms, 60% stated which patients should initiate basal or nutritional ...

Hospitalized patients with complex dietary restrictions often develop hyperglycemia, or high blood sugar. This occurs in roughly one-quarter to one-half of these patients and can lead to serious ...

Bigfoot Biomedical is doing its part to ensure that the possibility of building a smarter diabetes management system is more than just an urban legend. The tech maker has purchased a new algorithm ...

It is estimated that approximately 25%–30% of hospitalized adults have diabetes. Numerous studies have demonstrated the benefits of technological advances such as continuous glucose monitoring (CGM) ...

The Food and Drug Administration has cleared the Beta Bionics iLet ACE Pump and the iLet Dosing Decision Software for people six years of age and older with Type 1 diabetes. These two devices, along ...

Sliding scale insulin therapy uses your pre-meal blood sugar level to determine insulin dosage. Research indicates sliding scale insulin therapy is ineffective at managing blood sugar levels.

Looking to the European market, digital therapeutics company Amalgam Rx has scored an E.U. CE Mark for its insulin titration algorithm, called iSage Rx, and its white-label variants. This comes more ...

MILPITAS, Calif.--(BUSINESS WIRE)--Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, today announced the acquisition of a reinforcement learning ...

Helping toddlers manage their Type 1 diabetes—typically a difficult task, due to their constant growth and development, not to mention fussiness—may now be a bit easier. The FDA has expanded its ...